HER2/Neu Positive

18 registered clinical trials studyying HER2/Neu Positive — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk NCT03418961	SWOG Cancer Research Network	Phase 3
Terminated	Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis NCT02774681	Northwestern University	Phase 2
Completed	Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving NCT00194714	University of Washington	Phase 1 / Phase 2
Completed	Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients NCT02152943	M.D. Anderson Cancer Center	Phase 1
Completed	Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Tha NCT01816035	University of Washington	Phase 1
Completed	Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receivi NCT01922921	University of Washington	Phase 1 / Phase 2
Completed	Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck C NCT01846091	Mayo Clinic	Phase 1
Active Not Recruiting	Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Brea NCT01750073	University of Nebraska	Phase 2
Completed	Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relaps NCT01434303	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Loca NCT01273610	City of Hope Medical Center	Phase 2
Terminated	MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer NCT01319539	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive NCT01327781	National Cancer Institute (NCI)	Phase 1
Completed	Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer NCT01275677	National Cancer Institute (NCI)	Phase 3
Terminated	Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer NCT01281163	National Cancer Institute (NCI)	Phase 1
Terminated	RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metas NCT01217411	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ NCT00555152	National Cancer Institute (NCI)	N/A
Completed	Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or NCT00785291	National Cancer Institute (NCI)	Phase 3
Completed	Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Ca NCT00513292	National Cancer Institute (NCI)	Phase 3